![]() ![]() Fourteen (12.0%) patients presented synchronous alterations. Only 57 (48.7%) remained genomically UC, reducing the UC rate by 24.8%. Still, in the EC, combining NGS plus FISH for ALK, patients were classified as 23 (19.7%) EGFR 20 (17.1%) KRAS five (4.3%) B-Raf proto-oncogene (BRAF) one (0.9%) Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) one (0.9%) STK11 one (0.9%) TP53, and nine (7.7%) ALK mutated. ![]() Retesting the EC with NGS led to the identification of at least one gene variant in 56 (47.9%) patients, totaling 68 variants among all samples. ![]() Using Sanger and FISH, patients were classified as EGFR-mutated ( n = 22, 18.8%), ALK-mutated ( n = 9, 7.7%), and unclassifiable (UC) ( n = 86, 73.5%). Subsequently, an NGS-based approach was applied and tested in an implementation cohort (IC) in clinical practice. Its applicability was assessed in small biopsies and cytology specimens previously tested for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutational status, comparing the molecular changes identified and the impact on clinical outcomes. Methods: In this study, a Sanger sequencing plus Fluorescence In Situ Hybridization (FISH) sequential approach was compared with a Next-Generation Sequencing (NGS)-based approach for the detection of actionable genomic mutations in an experimental cohort (EC) of 117 patients with advanced lung adenocarcinoma. Identification of targetable molecular changes is essential for selecting appropriate treatment in patients with advanced lung adenocarcinoma. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |